Paul Tudor Jones Regeneron Pharmaceuticals, Inc. Transaction History
Tudor Investment Corp Et Al
- $25.1 Billion
- Q4 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 28,570 shares of REGN stock, worth $20.4 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
28,570
Previous 37,651
24.12%
Holding current value
$20.4 Million
Previous $39.6 Million
48.58%
% of portfolio
0.08%
Previous 0.15%
Shares
20 transactions
Others Institutions Holding REGN
# of Institutions
1,487Shares Held
85.7MCall Options Held
1.53MPut Options Held
1.43M-
Vanguard Group Inc Valley Forge, PA9.29MShares$6.62 Billion0.12% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$6.02 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY7.06MShares$5.04 Billion0.41% of portfolio
-
State Street Corp Boston, MA4.83MShares$3.45 Billion0.14% of portfolio
-
Capital International Investors Los Angeles, CA4.74MShares$3.38 Billion0.66% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $76.5B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...